Key opportunities in the bio-pharmaceutical logistics market include the expansion in personalized medicine distribution, increased smart cold chain investments, rising demand for cell and gene ...

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...

The report highlights opportunities in emerging trends and innovations in the pharmaceutical outsourcing sector, offering insights into new contracts and M&A deals. It advises on navigating regulatory ...

The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and ...

Parthenon report says AI-led R&D is accelerating drug discovery and decision-making in India’s bio-pharma sector. From generative design to digital twins and LLM copilots, firms are building ...

Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have jointly patented ...

May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories (BIO.N), opens new tab reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and ...

BioMarin Pharmaceutical Inc.'s shares have stagnated since 2020 despite steady sales growth and profitability, making current valuations more compelling amid ambitious 2027 targets. Recent competitor ...